Novo Nordisk's Pipeline Arithmetic: When a Paediatric Win Can't Offset a Cardiology Retreat
Published on 09/09/2026 at 16:32 | Editorial boerse-global.de
The market's verdict on Novo Nordisk this week has been brutally simple: good news inside the core business barely registers, while setbacks outside it carry outsized weight. That asymmetry was on full display when the Danish drugmaker announced on the same day that it had pulled the plug on two late-stage trials for its heart-failure candidate Ziltivekimab — and simultaneously posted positive paediatric data for semaglutide. Investors chose to focus on the former.
The shares, trading at €38.73, now sit roughly 29% below their 52-week high of €54.86 and close to 6% under the 30-day average. Year-to-date, holders are nursing a 12% decline. The secondary source puts the stock at €38.98, with an RSI of 42.5 and a price about 6.2% below the 50-day moving average — technical signals that suggest little momentum in either direction, while annualised volatility of 40% points to continued nervousness.
The diversification problem that won't go away
Ziltivekimab was meant to be the answer to a persistent question: can Novo Nordisk be more than a GLP-1 shop? Targeting heart failure, the drug was supposed to provide a second pillar beyond obesity and diabetes. Instead, an independent data monitoring committee concluded that two of three late-stage studies had a low probability of yielding results that would diverge from the earlier failed trial — prompting their early termination.
The third study, enrolling post-heart-attack patients, continues, with results expected in the first half of 2027. The company noted no new safety or tolerability concerns; efficacy was always the issue. That distinction matters little to a market that has spent months questioning whether the pipeline beyond weight-loss and diabetes drugs can deliver. It is a familiar pattern for pharma groups built on a blockbuster: success in the core franchise becomes the baseline expectation, while each attempt to branch into new indications turns into a high-stakes gamble with considerable reputational cost if it fails.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Where the growth story actually stands
What the market tends to overlook in the Ziltikevimab noise is that the core engine keeps producing. The STEP-Young phase 3 trial showed that after 68 weeks of semaglutide treatment, 40.4% of children aged six to under twelve no longer met the definition of obesity, hitting the primary endpoint of BMI reduction. That opens a largely untreated age group — commercially more significant over the long run than many peripheral indications, even if the share price failed to register it on the day.
Operationally, the oral Wegovy tablet has been available in Germany since early September, giving the company a foothold in the EU's largest pharma market with a formulation that appeals to patients wary of injections. China has also begun its approval review for the oral version, though no timeline has been given. Reuters has reported that Novo Nordisk will hold a capital markets day on 21 September — an opportunity to explain how it intends to fill the gap left by Ziltivekimab's retreat.
The competitive picture is complicated by Eli Lilly. The FDA has approved Mounjaro to reduce cardiovascular risk in high-risk type-2 diabetes patients, a move that intensifies pressure on Novo Nordisk's broader GLP-1 expansion. Meanwhile, agreed US price cuts — Ozempic and Wegovy will cost $350 per month through the TrumpRx channel — could paradoxically boost volumes enough to grow revenue despite thinner margins, though that arithmetic depends on the hoped-for demand materialising.
Reading the analyst tea leaves
Citi analysts reaffirmed their sell recommendation in early September with a price target of DKK 265, pointing to their weekly IQVIA tracker showing a slowdown in new GLP-1 prescriptions — with the oral Wegovy variant as the notable exception. That fits a broader narrative: the tablet is one of the few bright spots while prescription growth generally loses momentum.
The central question for investors is not really Ziltivekimab, whose failure was foreseeable after the first study was halted. It is how quickly oral Wegovy adoption and US pricing concessions translate into actual sales growth while Lilly presses its advantage. The company's €176.78 billion market capitalisation rests on a narrow product base, and the capital markets day will need to offer convincing answers about growth beyond the current franchise.
Until the final Ziltivekimab study on post-heart-attack patients reports in the first half of 2027, the shares will likely be judged primarily on oral Wegovy prescription numbers. The paediatric data demonstrates there is substance in the core — whether that suffices to meet expectations outside obesity and diabetes remains the uncertainty the current price reflects.
Ad
Novo Nordisk Stock: New Analysis - 9 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
